← All trials
NCT05829551
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2022
- Primary completion
- Aug 12, 2022
- Completion date
- Aug 12, 2022
- First posted
- Apr 25, 2023
- Last posted
- Apr 25, 2023
- Enrollment
- 88
- Arms / groups
- 10 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangdong Raynovent Biotech Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.